Diligence memo · auto-generated · as of July 3, 2026
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Vedanta Biosciences, Inc. operates in Biotech / Pharma, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Vedanta Biosciences, Inc. has raised $240M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $119M on 2023-03-01.
Most recent recorded round closed around 2023-03-01.
Valuation (modeled)modeled
Provath models Vedanta Biosciences, Inc. at approximately $2.0B (range $551M–$3.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.01× the median modeled value of Series D+ Biotech / Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 3.3 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Alto Pharmacy Holdings, Inc., Colossal Biosciences Inc., Seismic Therapeutic, Inc., Vignette Bio, Inc., PharmaCann Inc..
Peoplefiled
22 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.